Hyperhomocysteinemia, vascular function and atherosclerosis: Effects of vitamins

Cardiovascular Drugs and Therapy

Volumn 16, Issue 5, 2002, Pages 391-399

  Haynes, William G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; Endothelium; Folic acid; Homocysteine; Oxidant stress; Thrombosis; Vitamins

Indexed keywords

ANTIOXIDANT; CYANOCOBALAMIN; FOLIC ACID; PYRIDOXINE;

AMINO ACID BLOOD LEVEL; ARTERIAL PRESSURE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; ENDOTHELIUM; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MITOGENESIS; OXIDATIVE STRESS; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; THROMBOSIS; VASODILATATION; VITAMIN DEFICIENCY; VITAMIN INTAKE;

ARTERIOSCLEROSIS; AVITAMINOSIS; CORONARY DISEASE; FOLIC ACID DEFICIENCY; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY FAILURE, CHRONIC; METHIONINE; RISK FACTORS; THROMBOSIS; VITAMIN B 12 DEFICIENCY; VITAMIN B 6 DEFICIENCY; VITAMINS;

EID: 0036999105     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022130217463     Document Type: Conference Paper

References (76)

1. Mudd SH, Levy HL, Scovby F. Disorders of transulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, 6th ed. New York: McGraw-Hill, 1989:693-734.
2. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128.
3. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, 6th ed. New York: McGraw-Hill, 1989:2049-2064.
4. Stampfer MJ, Malinow MR, Willett MC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
5. Jacques PF, Rosenberg IH, Rogers G, et al. Serum total homocysteine concentrations in adolescent and adult Americans: Results from the third national health and nutrition examination survey. Am J Clin Nutr 1999;69:482-489.
6. Kang SS, Passen EL, Ruggie N, Wong PWK, Sora J. Thermolabile defect of methylene-tetrahydrofolate reductase in coronary artery disease. Circulation 1993;88:1463-1469.
7. Rozen R. Genetic predisposition to hyperhomocysteinemia: Deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 1997;78:523-526.
8. Morita H, Kurihara H, Tsubaki S, et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 1998;18:1465-1469.
9. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. Circulation 1998;98:2520-2526.
10. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis risk in communities (ARIC) study. Circulation 1998;98:204-210.
11. Verhoeff BJ, Trip MD, Prins MH, Kastelein JJ, Reitsma PH. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis 1998;141:161-166.
12. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.
13. 6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995;346:85-89.
14. Nygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: The hordaland homocysteine study. Am J Clin Nutr 1998;67:263-270.
15. Guttormsen AB, Schneede J, Fiskerstrand T, Ueland PM, Refsum HM. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr 1994;124:1934-1941.
16. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993;13:1327-1333.
17. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986;77:1909-1916.
18. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-1914.
19. Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart MJ. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res 1982;16:490-493.
20. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydyl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992;89:10193-10197.
21. Hajjar KA, Mauri L, Jacovina AT, et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998;273:9987-9993.
22. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 1997;11:1157-1168.
23. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vivo: A model for the study of vascular injury. Thromb Res 1980;18:113-121.
24. De Groot PG, Willems C, Boers GHJ, et al. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 1983;13:405-410.
25. Wang H, Yoshizumi M, Lai K, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997;272:25380-25385.
26. Dudman NPB, Temple SE, Guo XW, Fu WY, Perry MA. Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats in vivo. Circ Res 1999;84:409-416.
27. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-318.
28. McCully KS, Ragsdale BD. Production of arteriosclerosis by homocysteinemia. Am J Pathol 1970;61:1-11.
29. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731-741.
30. Hladovec J. Experimental homocysteinemia, endothelial lesions, and thrombosis. Blood Vessels 1979;18:11-20.
31. Rolland PH, Friggi A, Barlatier A, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995;91:1161-1174.
32. Lentz SR, Sobey CG, Piegors DJ, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996;98:24-29.
33. Lentz SR, Malinow MR, Piegors DJ, Bhopatkar-Teredesai MB, Faraci FM, Heistad DD. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscler Thromb Vasc Biol 1997;17:2930-2934.
34. Celermajer DS, Sorensen K, Ryalls M, et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993;22:854-858.
35. Takawol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation 1997;95:1119-1121.
36. Izzo MR, Feldman MD, Wu CC, et al. Lowering plasma homocysteine improves brachial artery vasoreactivity in patients with coronary artery disease. Circulation 1995;92(Suppl I):I-708 (Abstract).
37. Kanani PM, Sinkey CA, Browning RL, Alleman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; (in Press).
38. Bellamy MF, McDowell IF, Ramsey MW, et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998;98:1848-1852.
39. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998;351:36-37.
40. Haynes WG, Sinkey CA, Kanani P. Acute methionine loading produces endothelial dysfunction in humans. J Invest Med 1997;45:210A.
41. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inemia: Restoration by folic acid. Clin Sci 1999;96:235-239.
42. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1993;77:1370-1376.
43. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262:10098-10103.
44. Emsley AM, Jeremy JY, Gomes GN, Angelini GD, Plane F. Investigation of the inhibitory effects of homocysteine and copper on nitric oxide-mediated relaxation of rat isolated aorta. Brit J Pharmacol 1999;126:1034-1040.
45. Upchurch GR, Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012-17017.
46. Hultberg B, Andersson A, Isaksson A. The cell-damaging effects of low amounts of homocysteine and copper ions in human cell line cultures are caused by oxidative stress. Toxicology 1997;123:33-40.
47. Brown JC, Rosenquist TH, Monaghan DT. ERK2 activation by homocysteine in vascular smooth muscle cells. Biochem Biophys Res Comm 1998;251:669-676.
48. Tang L, Mamotte CD, Van Bockxmeer FM, Taylor RR. The effect of homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis 1998;136:169-173.
49. Dalton ML, Gadson PF, Jr, Wrenn RW, Rosenquist TH. Homocysteine signal cascade: Production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997;11:703-711.
50. Southern FN, Cruz N, Fink LM, et al. Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg 1998;28:909-918.
51. Charpiot P, Bescond A, Augier T, et al. Hyperhomocysteinemia induces elastolysis in minipig arteries: Structural consequences, arterial site specificity and effect of captoprilhydrochlorothiazide. Matrix Biol 1998;17:559-574.
52. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997;96:1745-1749.
53. Fiorina P, Lanfredini M, Montanari A, et al. Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus. Am J Hypertens 1998;11:1100-1107.
54. Boushey CJ, Beresford SAA, Omenn GS, Molutsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-1057.
55. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-1781.
56. Montalescot G, Ankri A, Chadefaux-Vekemans B, et al. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. Int J Cardiol 1997;60:295-300.
57. Bots ML, Launer LJ, Lindemans J, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: The Rotterdam study. Arch Intern Med 1999;159:38-44.
58. Ridker PM, Buring JE, Manson JE, Hennekens CH. A prospective study of total homocysteine and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;19(Suppl):I-810 (Abstract).
59. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236.
60. Meleady R, Lindgren A, Boers GHJ, et al. Plasma homocysteine as a prognostic risk factor for vascular disease. Eur Heart J 1998;19(Suppl):8 (Abstract).
61. Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: A 10-year follow-up. Arterioscler Thromb Vasc Biol 1998;18:1895-1901.
62. Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 1997;11:217-223.
63. Taylor LM, Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 1999;29:8-19.
64. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998;158:2101-2106.
65. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosis. Lancet 1996;348:1120-1124.
66. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-1782.
67. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arterioscler Thromb Vasc Biol 1997;17:2554-2558.
68. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998;97:138-141.
69. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyperhomocyst(e)inaemia. Lancet 1998;351:263.
70. Daly L, Meleady R, Graham I. Fasting or post-methionine load homocysteine: Which should be measured in relation to vascular risk? Ir J Med Sci 1995;164(Suppl 15):6 (Abstract).
71. van den Berg M, Stehouwer CDA, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996;16:165-171.
72. van der Griend R, Haas FJ, Duran M, Biesma DH, Meuwissen OJ, Banga JD. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med 1998;132:67-72.
73. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ 1998;316:894-898.
74. Bostom AG, Gohh RY, Beaulieu AJ, et al. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 1997;127:1089-1092.
75. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-1015.
76. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and homocysteine concentrations. N Engl J Med 1999;340:1449-1454.